{"entity":{"id":"nct04390737","kind":"trial","name":"Evaluate the Safety and Clinical Activity of HH2853","aka":[],"tldr":"A phase 1/2 trial of HH2853 Tablets in non-Hodgkin lymphoma, epithelioid sarcoma and peripheral T-cell lymphomas, run by Haihe Biopharma Co., Ltd., now recruiting.","summary":"Evaluate the Safety and Clinical Activity of HH2853 is a phase 1/2 interventional study registered as NCT04390737 by Haihe Biopharma Co., Ltd., with 254 participants planned, started 2020-09-08 and due to reach its primary completion in 2027-12-31. Interventions recorded: HH2853 Tablets.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04390737","url":"https://clinicaltrials.gov/study/NCT04390737"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","epithelioid-sarcoma","peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["haihe-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04390737","phase":"1/2","setting":"A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of HH2853 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphomas or Advanced Solid Tumors","sponsor":"Haihe Biopharma Co., Ltd.","enrolled":254,"outcomes":[]},"route":"/trials/nct04390737/","neighbours":{"cancer":[{"id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"company":[{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","route":"/companies/haihe-biopharma/"}]}}